BioStem Technologies, Inc.
BioStem Technologies, Inc. (BSEM) Financial Performance & Income Statement Overview
Review BioStem Technologies, Inc. (BSEM) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
BioStem Technologies, Inc. (BSEM) Income Statement & Financial Overview
Explore comprehensive income reports for BioStem Technologies, Inc. BSEM, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $102.87M | $82.56M | $74.49M | $41.90M |
| Cost of Revenue | $3.59M | $4.24M | $3.80M | $2.28M |
| Gross Profit | $99.28M | $78.32M | $70.69M | $39.63M |
| Gross Profit Ratio | $0.97 | $0.95 | $0.95 | $0.95 |
| R&D Expenses | $1.27M | $482495.00 | $85154.00 | $70748.00 |
| SG&A Expenses | $89.53M | $68.49M | $61.79M | $34.95M |
| Operating Expenses | $90.80M | $69.03M | $61.87M | $35.02M |
| Total Costs & Expenses | -$94.39M | $73.26M | $65.67M | $37.30M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $65751.00 | $138478.00 | $142722.00 | $163942.00 |
| Depreciation & Amortization | $77847.00 | $54038.00 | $87623.00 | $53665.00 |
| EBITDA | $8.56M | $9.35M | $8.91M | $4.66M |
| EBITDA Ratio | $0.08 | $0.11 | $0.12 | $0.11 |
| Operating Income | $8.48M | $9.29M | $8.82M | $4.61M |
| Operating Income Ratio | $0.08 | $0.11 | $0.12 | $0.11 |
| Other Income/Expenses (Net) | -$63254.00 | -$139289.00 | -$142837.00 | -$165509.00 |
| Income Before Tax | $8.42M | $9.15M | $8.68M | $4.44M |
| Income Before Tax Ratio | $0.08 | $0.11 | $0.12 | $0.11 |
| Income Tax Expense | -$7.10M | $2.33M | $2.31M | $521.00 |
| Net Income | $15.52M | $6.82M | $6.36M | $4.44M |
| Net Income Ratio | $0.15 | $0.08 | $0.09 | $0.11 |
| EPS | $0.94 | $0.42 | $0.39 | $0.27 |
| Diluted EPS | $0.68 | $0.32 | $0.30 | $0.20 |
| Weighted Avg Shares Outstanding | $16.43M | $16.32M | $16.30M | $16.32M |
| Weighted Avg Shares Outstanding (Diluted) | $22.77M | $21.13M | $20.92M | $22.38M |
The company's financials show resilient growth, with revenue advancing from $41.90M in Q1 2024 to $102.87M in Q4 2024. Gross profit remained healthy with margins at 97% in Q4 2024 compared to 95% in Q1 2024. Operating income hit $8.48M last quarter, sustaining a consistent 8% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $8.56M. Net income rose to $15.52M, while earnings per share reached $0.94. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan